![]() |
市场调查报告书
商品编码
1696283
全球止血基质市场 - 2025 至 2033 年Global Hemostatic Matrix Market - 2025-2033 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
2024 年全球止血基质市场规模达到 27.4 亿美元,预计到 2033 年将达到 39.1 亿美元,2025-2033 年预测期内的复合年增长率为 4.8%。
止血基质是一种在手术过程中控制出血的专用医疗产品。它通常将可流动的明胶基质与凝血酶成分结合在一起,共同促进快速血液凝固。当传统方法(如烧灼、结扎或缝合)可能无效时,这种组合尤其有价值,例如在涉及大面积表面或难以进入的出血部位的情况下。
外科手术数量的不断增长,特别是创伤护理中的外科手术数量的增长,是止血基质市场发展的主要驱动力。例如,根据世界卫生组织(WHO)的资料,道路交通事故每年夺走超过119万人的生命,其中许多受害者出现严重出血,需要立即进行手术干预。
这凸显了创伤手术中对有效止血剂的需求日益增加,因为控制出血对于改善患者的治疗效果至关重要。随着创伤相关手术数量的增加,对此类产品的需求预计也会增长,特别是在事故发生率高或紧急医疗基础设施正在发展的地区。止血技术的进步进一步推动了这种需求,促进了更有效和多功能产品的开发,提高了手术效率和病人安全性。
驱动因素与约束因素
外科手术数量不断增加
全球止血基质市场正在因几个关键驱动因素而扩大,其中外科手术的增加是主要因素。随着全球人口老化,与年龄相关的健康问题越来越普遍,需要进行手术,例如关节置换和心血管手术。根据维吉尼亚大学消息,预计到2030年,美国20%的人口将年龄超过65岁,这将大大增加对此类手术的需求,预计这一趋势将推动对止血基质产品的需求,而止血基质产品对于在復杂的手术过程中控制出血至关重要。
除了人口因素外,产业主要参与者推出的创新产品也进一步推动了市场成长。例如,2023 年 4 月,奥林巴斯推出了其 EndoClot 产品系列,这是一系列专为胃肠道手术设计的止血剂。这包括有助于止血和提供黏膜下注射溶液的产品,这对于内视镜黏膜下剥离术 (ESD) 和内视镜黏膜切除术 (EMR) 等手术特别有益。这些产品有助于在内视镜检查过程中维持持久的黏膜提升,提高手术的效果和安全性。
总之,随着外科手术的增加以及对先进、有效的止血解决方案的需求增加,这些人口趋势和技术创新是推动全球止血基质市场成长的关键因素。所有这些因素都要求全球止血基质市场的发展。
产品召回
产品召回对全球止血基质市场造成了重大限制,因为它们可能导致重大经济损失、损害品牌声誉,最重要的是对病患安全构成风险。这些召回通常在产品使用过程中或透过品质控制流程发现安全性或有效性问题时发生。如果发现止血剂无效、污染或其他损害,则可能导致不良的手术后果,例如无法控制的出血或感染,从而危害患者的健康。
例如,2024 年 9 月,百特医疗(Baxter Healthcare)因稳定性研究期间发现的问题,自愿召回部分批次的 Tisseel Lyo 纤维蛋白密封套件。这些套件用于各种外科手术,此次召回凸显了确保产品品质和安全的重要性,特别是对于直接影响患者结果的医疗设备。此类召回凸显了止血产品的潜在风险,因为任何缺陷都可能导致手术期间严重的併发症。因此,上述因素可能会限制全球止血基质市场的潜在成长。
The global hemostatic matrix market reached US$ 2.74 billion in 2024 and is expected to reach US$ 3.91 billion by 2033, growing at a CAGR of 4.8% during the forecast period of 2025-2033.
A hemostatic matrix is a specialized medical product that controls bleeding during surgical procedures. It often combines a flowable gelatin matrix with a thrombin component, working together to facilitate rapid blood clotting. This combination is particularly valuable when traditional methods like cautery, ligatures, or sutures might not be effective, such as in cases involving large surface areas or difficult-to-access bleeding sites.
The growing number of surgical procedures, especially in trauma care, is a key driver for the hemostatic matrix market. For example, according to World Health Organization (WHO) data, road traffic accidents claim the lives of over 1.19 million people annually, with many of these victims experiencing severe bleeding that requires prompt surgical intervention.
This highlights the increasing need for effective hemostatic agents in trauma surgeries, where bleeding control is crucial for improving patient outcomes. The demand for such products is expected to grow as the number of trauma-related surgeries rises, particularly in regions with high rates of accidents or where emergency medical infrastructure is developing. This demand is further fueled by advancements in hemostatic technology, which has led to the development of more effective and versatile products, enhancing both surgical efficiency and patient safety.
Market Dynamics: Drivers & Restraints
Increasing Number of Surgical Procedures
The global hemostatic matrix market is expanding due to several key drivers, with the rise in surgical procedures being a primary factor. As the global population ages, there is an increasing prevalence of age-related health issues that necessitate surgeries, such as joint replacements and cardiovascular procedures. According to University of Virginia news, it is projected that by 2030, 20% of the U.S. population will be over the age of 65, which will significantly increase the demand for these types of surgeries This trend is expected to drive the need for hemostatic matrix products, which are crucial for controlling bleeding during complex surgical procedures.
In addition to demographic factors, innovative product launches by key players in the industry are further fueling market growth. For example, in April 2023, Olympus introduced its EndoClot portfolio, a line of hemostatic agents designed for gastrointestinal procedures. This includes products that aid in hemostasis and provide a submucosal injection solution, which is particularly beneficial for procedures such as endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR). These products help maintain a long-lasting mucosal lift during endoscopic procedures, enhancing both surgical effectiveness and safety.
Together, these demographic trends and technological innovations are key factors driving the growth of the global hemostatic matrix market, as more surgical procedures are performed and demand for advanced, effective bleeding control solutions increases. All these factors demand the global hemostatic matrix market.
Product Recalls
Product recalls represent a significant restraint in the global hemostatic matrix market, as they can lead to substantial financial losses, damage to brand reputation, and, most importantly, pose risks to patient safety. These recalls often occur when safety or efficacy issues are identified during product usage or through quality control processes. If a hemostatic agent is found to be ineffective, contaminated, or otherwise compromised, it can lead to adverse surgical outcomes such as uncontrolled bleeding or infections, which jeopardize patient health.
For example, in September 2024, Baxter Healthcare issued a voluntary recall for certain batches of its Tisseel Lyo Fibrin Sealant Kits due to issues detected during stability studies. These kits are used in various surgical procedures, and the recall underscores the importance of ensuring product quality and safety, especially for medical devices that directly affect patient outcomes. Such recalls highlight the potential risks associated with hemostatic products, as any defect can result in severe complications during surgeries. Thus, the above factors could be limiting the global hemostatic matrix market's potential growth.
The global hemostatic matrix market is segmented based on product type, form, application, end-user, and region.
The thrombin-based hemostatic matrix segment in product type is expected to dominate the global hemostatic matrix market with the highest market share
The thrombin-based hemostatic matrix products are designed to control bleeding during surgical procedures, particularly in situations where traditional methods, such as ligatures or cautery, are either impractical or ineffective. The matrix combines a gelatin-based substance with thrombin, an enzyme that promotes clot formation.
This combination enhances hemostasis through two primary mechanisms: mechanical action, where the matrix physically compresses the bleeding area, and biochemical action, where thrombin catalyzes the formation of a clot. The effectiveness of thrombin-based hemostatic matrices in controlling bleeding makes them invaluable across various clinical settings, particularly in cardiovascular, orthopedic, and trauma surgeries. These matrices are especially crucial in situations where surgeons need immediate bleeding control and other methods cannot achieve the desired results.
Research and development in the segment have further solidified its market position. For instance, a meta-analysis from an NCBI study in October 2023 focused on the effectiveness of Floseal, a thrombin-based hemostatic matrix, in minimizing blood loss during total knee arthroplasty (TKA). The study highlighted ongoing debates in the medical community about the matrix's ability to reduce transfusion requirements during TKA surgeries.
While some randomized controlled trials (RCTs) have demonstrated their benefits, other studies have questioned their overall effectiveness. Nevertheless, the growing body of research in this area continues to reinforce the relevance of thrombin-based matrices in surgery, especially for high-risk or complex procedures. This focus on clinical efficacy and product development by key industry players is expected to drive continued growth in the thrombin-based hemostatic matrix segment, ensuring its dominance within the broader hemostatic matrix market.
North America is expected to hold a significant position in the global hemostatic matrix market with the highest market share
In the North America region hemostatic matrix market is due to several critical factors. A major driver is the rising prevalence of chronic diseases, particularly cardiovascular diseases (CVD), diabetes, and obesity, all of which often require surgical intervention.
As CVD rates continue to increase, the demand for cardiovascular surgeries such as coronary artery bypass grafting (CABG), valve replacements, and other cardiac procedures also rises. According to the American Heart Association, in July 2024, more than 184 million people are expected to be affected by some form of CVD by 2050, and the total costs related to CVD are projected to triple to approximately $1.8 trillion. This trend underscores the growing need for effective hemostatic solutions to control bleeding during these complex procedures, further driving demand for hemostatic matrix products.
Additionally, North America benefits from a robust healthcare infrastructure, the presence of numerous key industry players, and strong government initiatives and regulatory support. This combination facilitates the rapid adoption of innovative medical technologies.
A notable example of innovation in the region is the approval of ETHIZIA, a hemostatic sealing patch by Ethicon, a Johnson & Johnson MedTech company. In November 2023, Ethicon received approval for ETHIZIA, a product designed to address challenging bleeding situations during surgeries. The patch is unique for its synthetic polymer technology, which makes it effective on both sides, allowing it to be used in both open and minimally invasive surgeries. ETHIZIA demonstrated the ability to stop bleeding in 80% of patients within 30 seconds, which is significantly faster than traditional fibrin sealant patches
These factors, along with continued investment in product development, clinical trials, and regulatory approvals, are solidifying North America's position as a dominant force in the hemostatic matrix market. The region's well-established healthcare system and commitment to medical innovation make it a primary hub for the adoption of advanced hemostatic solutions.
The major global players in the hemostatic matrix market include Pfizer Inc., Ethicon (Johnson & Johnson), Baxter International Inc., Becton, Dickinson and Company (BD), B. Braun SE, Integra LifeSciences Corporation., CryoLife, Inc. (Artivion, Inc), Advanced Medical Solutions Group plc, Aegis Lifesciences, Teleflex Incorporated., and HLB Cell among others.
The global hemostatic matrix market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
LIST NOT EXHAUSTIVE